Agustin Go Yip

Agustin Go Yip

Auto-generated profile, based on publicly available information

Agustin Go Yip

Department of Public Health and Primary Care, University Forvie Site, Robinson Way, Cambridge CB2 2SR, UK

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2005 in Neurology
Verified
Journal Article
Closed access
PDF file
AYA. G. Yip
A. G. Yip
AMA. C. McKee
A. C. McKee
RGR. C. Green
R. C. Green
JWJ. Wells
J. Wells
HYH. Young
H. Young
LFLindsay Farrer
Lindsay Farrer
Objective: To use neuropathologic data to examine the association between APOE genotype and cerebrovascular lesions commonly found in Alzheimer disease (AD), as well as neuritic senile plaque (SP) and neurofibrillary tangle (NFT) burden. Methods: The sample comprised brains from 96 men and 3 women who fulfilled NIA-Reagan criteria for intermediate to high likelihood of AD. Region-specific and global measures of gross cerebrovascular disease, arteriolosclerosis, white matter lesions, microinfarcts, amyloid angiopathy, neuritic SP, and NFT burden were compared among those who had at least one APOE-ε4 vs those who did not. Pairwise rank-order correlations between measures were calculated. The association between APOE ε4 status and measures of vascular and AD pathology, adjusting for age at death, sex, brain weight, and Braak stage, were evaluated. Results: APOE-ε4 was not associated with gross cerebrovascular pathology. Compared to those who were negative, brains from ε4 individuals had a greater degree of small vessel arteriolosclerosis (p = 0.04) and perivascular macrophage infiltration (p = 0.06), but not other markers of small vessel disease or white matter myelin loss. Microinfarcts in the deep nuclei were associated with ε4 (p = 0.009), whereas cortical and subcortical microinfarcts were not. There was a trend toward association between APOE genotype and amyloid angiopathy (p = 0.08), and ε4 was associated with neuritic SP burden, but not NFT. Conclusion: APOE-ε4 is associated with small vessel arteriolosclerosis, microinfarcts of the deep nuclei, neuritic senile plaque density, and amyloid angiopathy in patients with autopsy-proven Alzheimer disease (AD). These results suggest a role for ε4 in some of the microvascular changes commonly found in AD and are consistent with a potential amyloidogenic role for ε4.

12 January 2006 in Age and Ageing
Verified
Journal Article
Open access
PDF file
AYAgustin G. Yip
Agustin G. Yip
CBCarol Brayne
Carol Brayne
FMFiona E. Matthews
Fiona E. Matthews
Objective: to investigate a number of prospectively collected factors (sociodemographic, medical and behavioural) and their association with incident dementia in a population-based cohort. Design: nested case–control analysis (at 2 and 6 years) of a population-based cohort study. Setting: individuals aged 65 years and above from five centres in England and Wales: two rural (Cambridgeshire and Gwynedd) and three urban (Nottingham, Newcastle and Oxford). Participants: a total of 4,075 individuals from a detailed assessment group, with risk measured at baseline. Main outcome measure: incident dementia at 2 and 6 years. Methods: logistic regression was used to calculate crude odds ratios (ORs) for various risk factors and ORs adjusted for age, sex, education and social class. Results: age (90+ versus 65–69 years OR = 25.6, 95% confidence interval (CI) = 11.6–56.9) and sex (women versus men OR = 1.6, 95% CI = 1.1–2.4) were directly associated with dementia, with a trend by years of education (Ptrend = 0.02) but not social class. Poor self-perceived health (versus good) increased the risk for incident dementia (OR = 3.9, 95% CI = 2.2–6.9). Alcohol and smoking (never, past and current) were neither strongly protective nor predictive. Stroke was strongly related to incident dementia (OR = 2.1, 95% CI = 1.1–4.2), as was Parkinson’s disease (OR = 3.5, 95% CI = 1.3–9.3), and exposure to general anaesthesia (GA) was inversely associated with dementia development (OR = 0.6, 95% CI = 0.4–0.9, with a trend with increasing GA exposure; P = 0.003). Conclusion: in this large multicentre and long-term population-based study, some well-known risk factors for dementia, of vascular and Alzheimer’s type, are confirmed but not others. The association between self-perceived health—a robust predictor of later health outcomes—and incident dementia, independently of other potential risks, warrants further study.

1 September 2000 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
YNYolanda Narain
Yolanda Narain
AYAgustin Yip
Agustin Yip
TMTerence Murphy
Terence Murphy
CBCarol Brayne
Carol Brayne
DEDouglas Easton
Douglas Easton
DRDavid C Rubinsztein
David C Rubinsztein
A recent study suggested that the insertion (I) allele in intron 16 of the angiotensin converting enzyme gene (ACE) is associated with Alzheimer's disease (AD) risk. In our series of 239 necropsy confirmed late onset AD cases and 342 elderly non-demented controls aged >73 years, we found significantly different ACE genotype distributions in the case and control groups (p=0.007). Homozygotes for both the I and D alleles were associated with a higher risk compared to DI heterozygotes. While the APOEε4 allele was strongly associated with AD risk in our series, we found no evidence for an interaction between the APOE andACE loci. In addition, no interactions were observed between ACE and gender or age at death of the AD cases. A meta-analysis of all published reports (12 case-control series in total) suggested that both the II and IDACE genotypes are associated with increased AD risk (odds ratio (OR) for II v DD 1.36, 95% confidence interval (CI)=1.13-1.63, OR for DIv DD 1.33, 95% CI=1.14-1.53, p=0.0002).

1 July 2017 in Brain Stimulation
Verified
Journal Article
Closed access
AYAgustin G. Yip
Agustin G. Yip
MGMark S. George
Mark S. George
ATAron Tendler
Aron Tendler
YRYiftach Roth
Yiftach Roth
AZAbraham Zangen
Abraham Zangen
LCLinda L. Carpenter
Linda L. Carpenter

12 January 2005 in BMC Geriatrics
Verified
Journal Article
Open access
PDF file
AYAgustín G Yip
Agustín G Yip
RGRobert C Green
Robert C Green
MHMatthew Huyck
Matthew Huyck
LCL Adrienne Cupples
L Adrienne Cupples
LFLindsay Farrer
Lindsay Farrer
FGfor the MIRAGE Study Group
for the MIRAGE Study Group
Background: Nonsteroidal anti-inflammatory drugs (NSAID) use may protect against Alzheimer's disease (AD) risk. We sought examine the association between NSAID use and risk of AD, and potential effect modification by APOE-ε4 carrier status and ethnicity. Methods: The MIRAGE Study is a multi-center family study of genetic and environmental risk factors for AD. Subjects comprised 691 AD patients (probands) and 973 family members enrolled at 15 research centers between 1996 and 2002. The primary independent and dependent variables were prior NSAID use and AD case status, respectively. We stratified the dataset in order to evaluate whether the association between NSAID use and AD was similar in APOE-ε4 carriers and non-carriers. Ethnicity was similarly examined as an effect modifier. Results: NSAID use was less frequent in cases compared to controls in the overall sample (adjusted OR = 0.64; 95% CI = 0.38–1.05). The benefit of NSAID use appeared more pronounced among APOE-ε4 carriers (adjusted OR = 0.49; 95% CI = 0.24–0.98) compared to non-carriers, although this association was not statistically significant. The pattern of association was similar in Caucasian and African Americans. Conclusions: NSAID use is inversely associated with AD and may be modified by APOE genotype. Prospective studies and clinical trials of sufficient power to detect effect modification by APOE-ε4 carrier status are needed.

1 August 2017 in Journal of Affective Disorders
Verified
Journal Article
Closed access
CCChristine A. Conelea
Christine A. Conelea
NPNoah S. Philip
Noah S. Philip
AYAgustin G. Yip
Agustin G. Yip
JBJennifer L. Barnes
Jennifer L. Barnes
MNMatthew J. Niedzwiecki
Matthew J. Niedzwiecki
LCLinda L. Carpenter
Linda L. Carpenter